WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI - News), a global leader focused on improving the health and safety of people and the environment, has acquired Analytica of Branford, Inc., a recognized pioneer and leader in mass spectrometry (MS) and ion source technology. The acquisition is an integral part of PerkinElmer’s strategic commitment to continue to grow its human and environmental health portfolio. Terms of the acquisition were not disclosed.
With the completion of this acquisition, PerkinElmer will gain significant insight and intellectual property in the field of MS and ion source technology.
“Mass spectrometry has proven to be an essential tool in many fields and will continue to be of critical importance. Bringing Analytica’s technology and team of highly innovative experts in-house will dramatically increase our capabilities in this area,” said Richard Begley, Ph.D., president, Analytical Sciences, PerkinElmer. “The acquisition of Analytica will allow us to offer our customers access to critical technologies such as time-of-flight and quadrupole mass spectrometers and new ion sources that provide more complete information as well as better throughput.”
Analytica’s advanced technology complements PerkinElmer’s human and environmental health portfolio. For human health applications, mass spectrometry provides an extremely detailed profile of medically relevant materials in drug discovery and molecular diagnostics. This technology is also the cornerstone of environmental detection and analysis and industrial monitoring. Areas of applications include environmental analysis, pharmaceutical and nutraceutical materials analysis, forensics and food safety.
“This is a wonderful opportunity to apply our outstanding applications and solutions to PerkinElmer’s new and broader end markets,” said Craig Whitehouse, founder and former president of Analytica. “We look forward to combining our resources to develop and provide applications that are critical to people and the environment.”
PerkinElmer will integrate Analytica’s current manufacturing operations into its Shelton, CT facility, while utilizing Analytica’s existing Branford facility for R&D projects. Craig Whitehouse will become an employee of PerkinElmer and oversee PerkinElmer’s MS R&D operations.
Analytica is a pioneer, leading the way with new advances in the field of mass spectrometry. Located in Branford, Connecticut, Analytica was founded in 1987 by Craig Whitehouse, who developed one of the first electrospray ion sources for MS. Electrospray ionization sources interfaced to mass spectrometers have since become widely used tools in analytical applications. Since 1989, Analytica has been marketing its technology for existing mass spectrometers and acting as a supplier to other analytical instrument companies.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products decline or do not grow as anticipated; (2) global economic, political and other risks; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials, key components and supplies; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with health care industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems or the failure to successfully implement new systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) dividends we pay on our stock could be reduced or eliminated in the future; and (22) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Contact:
Investor Relations: PerkinElmer, Inc. Dave C. Francisco, 781-663-5677 or Media Contact: PerkinElmer, Inc. Stephanie R. Wasco, 781-663-5701 stephanie.wasco@perkinelmer.com or Additional Media Contact: PerkinElmer Analytical Sciences Chris P. Tessier, 203-402-6872 christopher.tessier@perkinelmer.com
